Biopharma titans Kite, Bluebird join forces to tackle HPV cancers
- Kite Pharmaceuticals and Bluebird Bio have struck a co-development and co-marketing pact for next-gen T cell receptor (TCR) candidates to fight HPV-related cancers.
- The companies will be utilizing Kite's existing pipeline of TCR product candidates and Bluebird's pioneering gene editing platform.
- Under the auspices of the deal, the two firms will share overall costs and profits, with Kite taking a leading a role in the U.S. while Bluebird may take the lead in the EU, according to Seeking Alpha.
The companies haven't released all the details of the collaboration yet—but Kite will expound on it during an investor meeting on Tuesday.
Kite has several pipeline candidates aimed at tackling HPV, including two phase I candidates, that it will keep developing.